Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of ...

Although we don't believe in timing the market or panicking over daily movements, we do like to keep an eye on market changes -- just in case they're material to our investing thesis. Array BioPharma ...

ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. So what: Normally ...

(Reuters) - Array BioPharma Inc on Tuesday forecast first-quarter and fiscal 2009 revenue below analysts' estimates, a day after it posted wider quarterly loss, sending its shares down as much as 11 ...

* Q4 revenue $33.8 million versus I/B/E/S view $28.6 million * Q4 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S * Array Biopharma Inc - ‍Entered into a license, development and ...

Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...